数据
资源
版本对比
免费注册
预约演示
免费注册
Tandem Diabetes Care
Diabetes
Care to Present New Early User Insights on the Tandem Mobi System at the
American Diabetes Association
Diabetes
Association’s 84th Scientific Sessions
2024-06-18
·
BioSpace
SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care, Inc.
Diabetes
Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and
diabetes
technology company, today announced its schedule of presentations for the
American Diabetes Association
Diabetes
Association’s (ADA) 84th Scientific Sessions taking place in Orlando, Florida from June 21-24. Product Theater The Company will host a Product Theater on Saturday, June 22 from 10:15 am - 11:00 am EDT at Product Theater #1. Meet Tandem Mobi: Tiny pump, big control. The future of Automated Insulin Delivery (AID) Presenters: Jordan Pinsker, MD, Chief Medical Officer at
Tandem Diabetes Care
Diabetes
Care Halis Kaan Akturk, MD, Associate Professor of Medicine and Pediatrics at the Barbara Davis Center for
Diabetes
,
University of Colorado
Cari Berget, MPH, RN, CDCES, Director of the PANTHER Program and Research Instructor in Pediatrics at Barbara Davis Center During this session, new early user insights will be presented on Tandem Mobi, the world’s smallest, durable AID system* that became commercially available in the United States in February of 2024. Presenters will discuss how the unique wearability features of Tandem Mobi combined with the Control-IQ algorithm ushers in a new generation of AID systems. The speakers will also cover the benefits of a small-sized insulin delivery system that allows the ability to disconnect for sports, swimming, and real-life scenarios, and how optimizing algorithm settings can help improve patient outcomes. “This groundbreaking data is the first presentation of Tandem Mobi user insights and demonstrate our continued commitment to advancing
diabetes
care through innovative technology,” said Dr. Pinsker. “Understanding these early Tandem Mobi insights is critical to help ensure our portfolio of
diabetes
solutions continues to create a positively different experience for our customers.” Poster Presentations From June 22 - June 24, the Company will also release data during the Poster Sessions in the Poster Hall.
Tandem
authors will be available for questions during the General Poster Sessions scheduled for Saturday, June 22 at 12:30 pm EDT. The t:slim X2 with Control-IQ Technology Overcomes Missed Boluses for Moderate Meals
Tandem Diabetes Care
Diabetes
Care Authors: Larry Fu, Principal Data Scientist; Alex Trahan, Sr. Manager, Data Science; Laurel Messer, PhD, MPH, RN, CDCES, Sr. Director of Medical Affairs; and Alex Constantin, PhD, Sr. Director, Data Science What Happens When People Don’t Bolus for Extended Periods of Time while Using the t:slim X2 with Control-IQ Technology?
Tandem Diabetes Care
Diabetes
Care Authors: Miranda R. Polin, Sr. Data Analyst II; Andy Johnson, Principal Data Analyst/Manager; Laurel Messer, PhD, MPH, RN, CDCES, Sr. Director of Medical Affairs; Alex Constantin, PhD, Sr. Director, Data Science; and Jordan Pinsker, MD, Chief Medical Officer High Time in Closed Loop for Control-IQ Technology with New Interoperable iCGM Sensor
Tandem Diabetes Care
Diabetes
Care Authors: Steph Habif, EdD, MS; Sabah Mufti, Senior Manager, Product Marketing; Michelle Manning, Principal Customer Feedback Scientist; Kevin Wu, Sr. Product Manager, Product Management; and Laurel Messer, PhD, MPH, RN, CDCES, Sr. Director of Medical Affairs High User Satisfaction and Ease of Use Scores with 6 Months Use of the
Tandem
t:connect Mobile Application
Tandem Diabetes Care
Diabetes
Care Authors: Kimia Assadi, MPH, Sr. Medical Writer I; Michelle Manning, Principal Customer Feedback Scientist/Manager; Jordan Pinsker, MD, Chief Medical Officer; and Laurel Messer, PhD, MPH, RN, CDCES, Sr. Director of Medical Affairs New Paradigms for Wearability with the Tandem Mobi System: Mobi Can Be Worn Many Ways, Early Data Indicate
Tandem Diabetes Care
Diabetes
Care Authors: Steph Habif, EdD, MS; Michelle Manning, Principal Customer Feedback Scientist; Scott Leas, Director of Business Analytics; Lexi Morgan, Product Manager, Commercial Marketing; and Laurel Messer, PhD, MPH, RN, CDCES, Sr. Director of Medical Affairs Exhibitor Information The Company will also be an exhibitor during the full duration of ADA at Booth #1621. Tandem Mobi will be available for demonstration with the recently launched
Dexcom
G7 Continuous Glucose Monitoring (CGM) System integration. The t:slim X2, the #1 rated automated insulin delivery system (AID) system**, will also be on display as the first insulin pump to be compatible with three CGMs:
Dexcom
G6,
Dexcom
G7 and Abbott FreeStyle Libre 2 Plus. Other Presentations Dr. Laurel Messer, Sr. Director of Medical Affairs at
Tandem Diabetes Care
Diabetes
Care, will also participate in the “Bridging Technology and Therapies to Improve
Diabetes
Outcomes” panel during diaTribe Musings LIVE on Thursday, June 20 from 5:00 - 7:30 pm EDT at The Gaylord Palms Resort, Emerald Bay Plaza. * As of June 2024. Data on file,
Tandem Diabetes Care
Diabetes
Care. ** dQ&A US
Diabetes
Connections Patient Panel Report, Q3 2023 About
Tandem Diabetes Care
Diabetes
Care
Tandem Diabetes Care
Diabetes
Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of
diabetes
management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company’s pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology.
Tandem Diabetes Care
Diabetes
Care is based in San Diego, California. For more information, visit tandemdiabetes.com. Follow
Tandem Diabetes Care
Diabetes
Care on X @tandemdiabetes; use #tslimX2 #TandemMobi and #TandemDiabetes. Follow
Tandem Diabetes Care
Diabetes
Care on Facebook at . Follow
Tandem Diabetes Care
Diabetes
Care on LinkedIn at . © 2024
Tandem Diabetes Care, Inc.
Diabetes
Care, Inc. All rights reserved.
Tandem Diabetes Care
Diabetes
Care,
Tandem
logos, Control-IQ, t:slim X2, and Tandem Mobi are trademarks of
Tandem Diabetes Care, Inc.
Diabetes
Care, Inc. in the United States and/or other countries.
Dexcom
,
Dexcom
G6, and
Dexcom
G7 are either registered trademarks or trademarks of
Dexcom, Inc.
in the United States and/or other countries. FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other third-party marks are the property of their respective owners. Responsible Use of Control-IQ technology Control-IQ technology does not prevent all highs and lows. Users must still bolus for meals and actively manage their
diabetes
. Visit tandemdiabetes.com/responsible-use for additional important safety information. Important Safety Information
RX ONLY
. Indications for Use: Tandem Mobi system: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of
insulin
, at set and variable rates, for the management of
diabetes mellitus
in persons requiring
insulin
. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient, home use and requires a prescription. The pump is indicated for use in individuals 6 years of age and greater. t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology is intended for the subcutaneous delivery of
insulin
, at set and variable rates, for the management of
diabetes mellitus
in people requiring
insulin
. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is intended for single patient use. The pump is indicated for use with NovoLog or Humalog U-100 insulin. The pump is indicated for use in individuals 6 years of age and greater. Control-IQ technology: Control-IQ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ technology is intended for the management of
Type 1 diabetes mellitus
in persons 6 years of age and greater. Control-IQ technology is intended for single patient use. Control-IQ technology is indicated for use with NovoLog or Humalog U-100 insulin. WARNING: Control-IQ technology should not be used by anyone under the age of 6 years old. It should also not be used in patients who require less than 10 units of
insulin
per day or who weigh less than 55 pounds. Control-IQ technology is not indicated for use in pregnant women, people on dialysis, or critically ill patients. Do not use Control-IQ technology if using
hydroxyurea
. Users of a
Tandem
insulin pump and Control-IQ technology must use the insulin pump, CGM, and all other system components in accordance with their respective instructions for use; test blood glucose levels as recommended by their healthcare provider; demonstrate adequate carb-counting skills; maintain sufficient
diabetes
self-care skills; see healthcare provider(s) regularly; and have adequate vision and/or hearing to recognize all functions of the pump, including alerts, alarms, and reminders. The
Tandem
pump and the CGM transmitter and sensor must be removed before MRI, CT, or diathermy treatment. Visit tandemdiabetes.com/safetyinfo for additional important safety information. View source version on businesswire.com: Contacts Investor Contact: 858-366-6900 IR@tandemdiabetes.com Source:
Tandem Diabetes Care, Inc.
Diabetes
Care, Inc. View this news release online at:
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Tandem Diabetes Care, Inc.
American Diabetes Association
The University of Colorado
[+3]
适应症
糖尿病
1型糖尿病
靶点
-
药物
NNC0268-0965
羟基脲
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务